 |
|
|
| |
NVR 3-778, a First-in-class HBV Core Inhibitor,
Alone and in Combination with Pegylated-interferon
(peg-IFN alpha-2a), in Treatment-naïve HBeAg-positive Patients:
Early Reductions in HBV DNA and HBeAg
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
M-F Yuen,1 DJ Kim,2 F Weilert,3 H L-Y Chan,4 J Lalezari,5 SG Hwang,6 T Nguyen,7 S Liaw,8 N Brown,8 K Klumpp,8 L Flores,8 G Hartman,8 EJ Gane9
1Queen Mary Hospital, University of Hong Kong, Hong Kong; 2Hallym University, Chuncheon Sacred Heart Hospital, Gangwon-do, Republic of Korea; 3Waikato Hospital, Hamilton, New Zealand; 4Prince of Wales Hospital, Chinese University
of Hong Kong, Hong Kong; 5Quest Clinical Research, San Francisco, CA, USA; 6CHA Bundang Medical Center, Gyeonggi-do, Republic of Korea; 7Research and Education, Inc., San Diego, CA, USA; 8Novira Therapeutics, Doylestown, PA, USA; 9Auckland Clinical Studies, Auckland, New Zealand
|
| |
|
|
|
|
|
